TG Therapeutics Management
Management criteria checks 3/4
TG Therapeutics' CEO is Mike Weiss, appointed in Dec 2011, has a tenure of 12.42 years. total yearly compensation is $10.44M, comprised of 8.4% salary and 91.6% bonuses, including company stock and options. directly owns 5.66% of the company’s shares, worth $130.23M. The average tenure of the management team and the board of directors is 12.4 years and 10.5 years respectively.
Key information
Mike Weiss
Chief executive officer
US$10.4m
Total compensation
| CEO salary percentage | 8.4% |
| CEO tenure | 12.4yrs |
| CEO ownership | 5.7% |
| Management average tenure | 12.4yrs |
| Board average tenure | 10.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$41m |
| Dec 31 2023 | n/a | n/a | US$13m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$176m |
| Mar 31 2023 | n/a | n/a | -US$169m |
| Dec 31 2022 | US$10m | US$875k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$239m |
| Jun 30 2022 | n/a | n/a | -US$288m |
| Mar 31 2022 | n/a | n/a | -US$326m |
| Dec 31 2021 | US$43m | US$1m | -US$348m |
| Sep 30 2021 | n/a | n/a | -US$343m |
| Jun 30 2021 | n/a | n/a | -US$345m |
| Mar 31 2021 | n/a | n/a | -US$319m |
| Dec 31 2020 | US$32m | US$1m | -US$279m |
| Sep 30 2020 | n/a | n/a | -US$231m |
| Jun 30 2020 | n/a | n/a | -US$206m |
| Mar 31 2020 | n/a | n/a | -US$189m |
| Dec 31 2019 | US$13m | US$637k | -US$173m |
| Sep 30 2019 | n/a | n/a | -US$187m |
| Jun 30 2019 | n/a | n/a | -US$159m |
| Mar 31 2019 | n/a | n/a | -US$167m |
| Dec 31 2018 | US$14m | US$656k | -US$173m |
| Sep 30 2018 | n/a | n/a | -US$150m |
| Jun 30 2018 | n/a | n/a | -US$148m |
| Mar 31 2018 | n/a | n/a | -US$132m |
| Dec 31 2017 | US$10m | US$525k | -US$118m |
Compensation vs Market: Mike's total compensation ($USD10.44M) is above average for companies of similar size in the UK market ($USD2.33M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
CEO
Mike Weiss (57 yo)
12.4yrs
Tenure
US$10,435,150
Compensation
Mr. Michael S. Weiss, Esq. J.D. also known as Mike, serves as Director of Urica Therapeutics, Inc. He has been an Executive Chairman of Mustang Bio, Inc. since January 2017 and served as its Interim Presid...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 12.4yrs | US$10.44m | 5.66% $ 130.2m | |
| CFO, Corporate Secretary & Treasurer | 12.4yrs | US$1.97m | 0.47% $ 10.8m | |
| Senior Vice President of Corporate Communications | no data | no data | no data | |
| Chief Commercialization Officer | 5.9yrs | no data | no data |
12.4yrs
Average Tenure
Experienced Management: 0VGI's management team is seasoned and experienced (12.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 12.4yrs | US$10.44m | 5.66% $ 130.2m | |
| Lead Independent Director | 12.1yrs | US$437.50k | 0.15% $ 3.4m | |
| Independent Director | 9.4yrs | US$397.50k | 0.17% $ 3.9m | |
| Independent Director | 11.5yrs | US$395.00k | 0.15% $ 3.5m | |
| Independent Director | 4.1yrs | US$392.50k | 0.075% $ 1.7m | |
| Independent Director | 8.9yrs | US$395.00k | 0.15% $ 3.5m |
10.5yrs
Average Tenure
57.5yo
Average Age
Experienced Board: 0VGI's board of directors are seasoned and experienced ( 10.5 years average tenure).